Kodikaz Therapeutic Solutions — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kodikaz Therapeutic Solutions is an early-stage biotech (founded 2021) pioneering a proprietary, non-viral targeted delivery platform called Zip-Code™ Technology. The platform is based on the novel discovery of horizontal gene transfer mechanisms in human cells, which Kodikaz engineers into synthetic DNA constructs (TaRGeT Zip-Codes™) that can deliver large payloads like gene editors or cytotoxic agents with high cell specificity. Led by a team with industry and academic expertise, the company is building a library of Zip-Codes for cancer applications, positioning itself to address key limitations of viral gene therapy vectors. It is currently in a pre-clinical, pre-revenue stage.

Oncology

Technology Platform

Zip-Code™ / TaRGeT Zip-Codes™: A non-viral, synthetic DNA-based platform leveraging engineered human horizontal gene transfer mechanisms for cell-specific delivery of large therapeutic payloads (>20kb) like gene editors, RNAi, or cytotoxic agents.

Opportunities

The platform addresses major limitations of viral gene therapy (immunogenicity, payload size) in a large and growing oncology market.

Its modular, non-viral design could enable a pipeline of targeted therapies across multiple cancer types and, eventually, other disease areas requiring precise cell-specific delivery.

Risk Factors

The core science of human horizontal gene transfer requires extensive validation.

Translating the platform into safe, effective, and manufacturable drugs faces significant technical hurdles.

As a pre-revenue startup, it is highly dependent on external capital in a competitive funding and technological landscape.

Competitive Landscape

Kodikaz competes in the crowded non-viral drug delivery space, which includes companies developing lipid nanoparticles, polymer-based vectors, and other synthetic delivery technologies. Its differentiation hinges on the novelty and claimed cell-specificity of its biology-derived Zip-Codes, which remains unproven compared to more established delivery modalities.

More companies in Drug Delivery & Formulation →More companies in United States →